سعر لينبارزا 150مجم 56 قرص 2025

Lynparza 150 mg olaparib film-coated tablets, pack of 56, by AstraZeneca (listed in Egypt).

• Maintenance treatment of BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy.Population: AdultsDailyMed (U.S. National Library of Medicine)
• In combination with bevacizumab: first-line maintenance of HRD-positive advanced ovarian, fallopian tube or primary peritoneal cancer.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Maintenance treatment of BRCA-mutated recurrent ovarian, fallopian tube or primary peritoneal cancer in response to platinum chemotherapy.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (at least 10%) as monotherapy in pooled trials: nausea, fatigue, anaemia, vomiting, diarrhoea, decreased appetite, headache, dysgeusia, cough, neutropenia, dyspnoea, dizziness, dyspepsia, leukopenia and thrombocytopenia.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• None listed in the US label.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Myelodysplastic syndrome/acute myeloid leukaemia (about 1.2% cumulative incidence, about half fatal): do not start until recovered from prior chemotherapy haematological toxicity; monitor blood counts.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Pneumonitis, including fatal cases (about 1%): interrupt for new or worsening respiratory symptoms and discontinue if confirmed.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Venous thromboembolism including pulmonary embolism (8% in prostate cancer trials): monitor and treat as appropriate.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong or moderate CYP3A inhibitors (e.g. itraconazole, clarithromycin; fluconazole, verapamil)Increase olaparib exposure; avoid, or reduce the olaparib dose to 100 mg (strong) or 150 mg (moderate) twice daily.DailyMed (U.S. National Library of Medicine)
• Strong or moderate CYP3A inducers (e.g. rifampicin, carbamazepine)Decrease olaparib exposure and may reduce efficacy; avoid.DailyMed (U.S. National Library of Medicine)
• Other myelosuppressive anticancer agentsPotentiation and prolongation of myelosuppression.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm based on mechanism and animal data (teratogenicity and embryo-fetal toxicity in rats at exposures below human exposure); no human data. Verify pregnancy status before starting.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; do not breastfeed during treatment and for 1 month after the last dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Olaparib: Inhibits PARP enzymes (PARP1, PARP2, PARP3) involved in DNA repair and traps PARP-DNA complexes, causing DNA damage and cancer cell death, especially in tumours with homologous recombination repair defects such as BRCA mutations (US label).